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was 2 at ≥ 6 months follow-up. 1 DPBN-patient had G3 
xerostomia at month 3 that reduced to G1 thereafter. 
Conclusions; There were no local recurrences in the DPBN-
group. We did not observe significant differences in LC, RC, 
DC or OS until now. Due to mucosal LT, the DPBN-DPP has 
been adapted. Since then, no G4 mucosal LT was observed. 
Another 66 patients will be recruited for the study.  
   
PD-0421   
HER3 pathway analysis in radiation plus concurrent 
cisplatin or anti-EGFR moAb for head and neck cancer 
S. Benavente1, L. Cerezo2, A. De la Torre3, J. Contreras4, M. 
Semidey5, M. Alberola5, J. Hernández5, J. Giralt1 
1Hospital Vall d´Hebron, Radiation Oncology, Barcelona, 
Spain  
2Hospital de la Princesa, Radiation Oncology, Madrid, Spain  
3Hospital Puerta de Hierro, Radiation Oncology, Madrid, 
Spain  
4Hospital Carlos Haya, Radiation Oncology, Málaga, Spain  
5Hospital Vall d'Hebron, Pathology, Barcelona, Spain  
 
Purpose/Objective: Concurrent cisplatin and radiation (cisp-
RT) can achieve high locoregional control and survival for 
locally advanced head and neck cancer (LAHNC) particularly 
in the oropharynx, HPV+, and non-smokers. Recent 
retrospective reviews challenge the role of cetuximab plus 
radiation in this population suggesting inferior outcomes, 
which needs to be further confirmed. HPV negative head and 
neck cancer patients seem to do far worse with current 
strategies. This study compares concurrent cisp-RT with 
radiation plus anti-EGFR moAb (anti-EGFR-RT) in LAHNC in a 
population that is mainly HPV negative. The prognostic value 
of HER3 pathway-related biomarkers is explored. 
Materials and Methods: From 1999 to 2010, 108 LAHNC 
patients with oral cavity, oropharynx, hypopharynx or larynx 
tumors received definitive treatment with cisp-RT (n= 71) or 
anti-EGFR-RT (n=37). Of these, 86 patients had tissue 
available for HPV analysis (PCR and p16), and 48 for HER3 
pathway analysis. Outcomes were analyzed by the Kaplan-
Meier method, Cox model and competing-risks analysis tools. 
Results: 88% of the analyzed samples were HPV negative. 
Patient characteristics include 77% smokers, 70% heavy 
alcohol intake, 49% T4 and 69% N2-3. The anti-EGFR-RT 
patients were older. At a median follow-up of 4.2 years, the 
2- and 5-year locoregional failure rates were 34.1% and 41.8% 
for cisp-RT vs 60.1% and 71.5% for anti-EGFR-RT (p=0.015). 
These differences remained significant for progression-free 
survival (p=0.0006) and were lost when distant metastasis 
was the only site of relapse (p=0.24). Metastasis-only relapse 
occurred in 14.8% of patients. In multivariate analysis, cisp-
RT predicted for locoregional relapse (HR=0.53, 95%CI: 0.31-
0.92, p=0.024) and progression-free survival (HR=0.44, 95%CI: 
0.27-0.71, p=0.0009), whereas hypopharynx/larynx primaries 
(HR=5.13, 95%CI: 1.50-17.51, p=0.013) and T4 tumors 
(HR=2.95, 95%CI: 1.05-8.31, p=0.041) predicted for 
metastasis-only relapse. Subgroup analysis of HER3 pathway-
related biomarkers adjusted for significant risk variables 
identified overexpression of pS6 (p=0.009) and p53 (p=0.049) 
as prognostic for locoregional failure, and pS6 (p=0.016) and 
HER3 (p=0.049) expression for metastasis-only relapse.  
Conclusions: Superior outcomes with concurrent cisp-RT in 
LAHN patients are observed in a predominantly HPV negative 
population. It is of clinical relevance that 
hypopharynx/larynx primaries and T4 tumors predicted for 
metastasis as the only site of relapse in such a high risk 
group. Exploratory analyses suggest that pS6 and p53 
expression predict for locoregional failure and that pS6 and 
HER3 do for metastasis-only relapse. 
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Purpose/Objective: Data quality of routine patients is of 
vital importance when creating an infrastructure for rapid 
learning. The aim of this work is to provide a platform that 
enables rapid learning for laryngeal carcinoma patients and 
prove the clinical relevance of a survival prediction model as 
a first step to multi institutional rapid learning. In this study 
we present a first rapid learning approach that combines 
learning a decision support system from MAASTRO Clinic 
('training cohort') and validating it in both the Illawarra 
Cancer Care Centre ('clinical cohort') and the RTOG-91-11 
clinical trial dataset ('trial cohort'). 
Materials and Methods: Data extraction and mining tools 
were used to collect the input parameters from the clinical 
cohort's OIS system (MosaiQ). The training cohort was used to 
determine the prognosis range for good, medium and poor 
prognosis patients so it could be applied to the clinical cohort 
and to validate the new implementation of the model. To 
evaluate the model performance the Area Under the Curve 
(AUC) spread for each dataset was calculated using 
bootstrapping. A similar approach was applied to the 
radiotherapy only arm of the trial cohort. The resulting 
Kaplan-Meier survival curves for the good, medium and poor 
prognosis groups are displayed for each separate cohort. 
Results: Data mining identified 125 laryngeal carcinoma 
patients, resulting in 109 that were eligible to be evaluated 
by the model to predict 2 year survival. Bootstrapping 
resulted in a normally distributed AUC reliability interval 
(95% CI) of 0.61 to 0.84, 0.47 to 0.67 and 0.74 to 0.82 for the 
clinical, trial and training cohorts respectively. The predicted 
prognostic survival groups resulted in the Kaplan Meier curves 
presented in Figure 1. The survival prediction thresholds to 
create the poor, medium and good prognosis groups were 57% 
and 81% chance of 2 year survival. This resulted in a group 
distribution of 47%, 42% and 11% and 53%, 42% and 5% for the 
